An efficient directed cell migration assay
An efficient directed cell migration assay
批准号:
8648454
负责人:
Timothy George Burland
金额:
$14.43万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2016-04-30
关键词:
AffectAntineoplastic AgentsAutomationBehaviorBiocompatibleBiological AssayCancer CenterCell LineCellsCharacteristicsChemicalsChemotactic FactorsChemotaxisCollaborationsComplexDataDepositionDetectionDevelopmentDrug TargetingEncapsulatedEpidermal Growth FactorEventExcisionExclusionGelGoalsGrowth FactorIn VitroInvestigationKineticsKnowledgeLaboratory ResearchLeadLettersMDA MB 231Malignant NeoplasmsMeasurementMeasuresMembraneMethodsMicrofluidicsMicroscopyMigration AssayMolecularOrnithorhynchus anatinusPhasePolymersPositioning AttributeReaderReagentRelative (related person)ReproducibilityResearchResourcesRunningSeriesSiliconesSmall Business Innovation Research GrantSpecific qualifier valueSpecificitySystemTechnologyTestingTherapeuticTimeUniversitiesWisconsinassay developmentbasecancer cellcell motilitycellular targetingcontrolled releasecost effectivedesigndrug discoveryhigh throughput screeningmetastatic processprogramspublic health relevanceresponsescreeningsmall moleculesmall molecule librariessuccesstechnological innovation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
The goal of this SBIR project is to design and develop an efficient, automation-
compatible Directed Cell Migration (DCM) 96-well Assay that distinguishes chemokinetic from
chemotactic behavior. Cell migration is currently assayed using trans-membrane well inserts,
microfluidic systems and various versions of scratch assays. These methods are expensive and
provide inconsistent data. Due to its importance in cancer and associated metastatic processes,
cell migration is intensively studied and in vitro cell migration assays are routinely used in drug
discovery programs aimed at identifying new cancer therapeutics. An important characteristic of
cancer cells is their ability to detect chemoattractant gradients and migrate in response to them.
A major barrier to efficient screening of candidate cancer therapeutics affecting directed cell
migration is the lack of affordable cell based assays that are robust, physiologically relevant,
reproducible and cost-effective to perform. Platypus Technologies LLC has developed and
commercialized two distinct products for the study of cell migration. The Oris" DCM assay
proposed in this Phase I project builds on the success of the Platypus Oris" Pro cell migration
assay product. Specifically, the Oris" DCM assay will allow measurement of directed cell
migration in response to chemoattractants, thereby facilitating identification and development of
lead therapeutic compounds that target cellular responses to chemoattractants. The proposed
assay is amenable to automation and to readout by microscopy, multi-well plate readers, and
high content imagers. Major additional benefits of the proposed assay format include ability to
1) visualize cell movement in real-time and 2) perform multiplexed secondary screens to
elucidate mechanism of action of the test compound via cytostaining within the same well that
the primary chemotaxis assay was run. This latter benefit is an extraordinary advantage that
increases the knowledge-generating power of the research dollar by conserving reagents
including compounds, cells, etc and resources that would otherwise be consumed in repetitive
testing required by competing formats.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An Efficient Fully 3-Dimensional Cell Migration Assay
-
批准号:8713184
-
项目类别:
-
资助金额:$14.74万
-
财政年份:2014
-
负责人:Timothy George Burland
-
依托单位:
High throughput cell migration assay amenable to high content imaging
-
批准号:8217120
-
项目类别:
-
资助金额:$39.39万
-
财政年份:2009
-
负责人:Timothy George Burland
-
依托单位:
海外基金